EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58

Paul M Haller iD, Stephen D Wiviott, David D Berg, Petr Jarolim, Erica L Goodrich, Deepak L Bhatt, Ingrid Gause-Nilsson, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Itamar Raz, Marc S Sabatine und 1 weitere

ESC Heart Failure · 01.12.2025 · 12 (6) · 3981-3986

DOI: 10.1002/ehf2.15415 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 15.09.2025. Verfasst von Paul M Haller und 12 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetes Mellitus, Type 2, Galectin 3. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, AstraZeneca, Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Galectin-3 (Gal-3) is a circulating biomarker of fibrosis, with higher levels being associated with an increased risk of progression of heart failure and kidney disease. Patients with type 2 diabetes mellitus (T2DM) are at increased risk of both.

Methods

DECLARE-TIMI 58 was a randomized, placebo-controlled trial of dapagliflozin in patients with T2DM with or at high risk for atherosclerotic cardiovascular disease and creatinine clearance ≥60 mL/min. In a nested biomarker substudy, Gal-3 was measured at baseline and in adjusted analyses associated with the prespecified kidney-specific composite endpoint [Kidney-EP; sustained ≥40% decrease in estimated glomerular filtration rate (eGFR) to <60 mL/min, new end-stage kidney disease or adjudicated kidney-related death].

Results

Among 14 530 pts, median Gal-3 was 14.9 ng/mL [interquartile range (IQR), 11.9, 18.4]. Gal-3 was weakly associated with urine albumin creatinine ratio (r = 0.098, P < 0.0001) and eGFR (r = −0.27, P < 0.001) at baseline and independently associated with the Kidney-EP:adj hazard ratio (HR) 1.15 [95% confidence interval (CI) 1.03, 1.28] per 1-SD log (Gal-3), P = 0.013. Dapagliflozin significantly reduced the relative risk of the Kidney-EP across quartiles of baseline Gal-3 [overall HR 0.45 (95% CI 0.23, 0.85), P < 0.0001; P interaction = 0.87]. A greater risk difference was observed with dapagliflozin in patients with higher Gal-3, in whom a higher absolute risk at baseline was observed [absolute risk reduction (ARR) Q4 1.9 (95% CI 0.6, 3.2) vs. Q1 0.6% (−0.1, 1.3), ARR P trend 0.048].

Conclusions

Plasma Gal-3 is independently associated with the progression of kidney dysfunction in patients with T2DM and normal kidney function. There was a gradient of greater absolute benefit for reducing kidney disease progression in patients treated with dapagliflozin and with higher Gal-3 concentrations at baseline, in whom a higher absolute risk was observed. Registration: clinicaltrials.gov (NCT01730534).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesDiabetes Mellitus, Type 2Galectin 3Glomerular Filtration RateKidneyDiabetic NephropathiesHumansMaleFemaleMiddle AgedBiomarkersSodium-Glucose Transporter 2 InhibitorsAgedDouble-Blind MethodDisease ProgressionFollow-Up StudiesBlood ProteinsGalectins

Stichwörter der Autor:innen

dapagliflozingalectin‐3kidney diseaserenal functionsglt2‐inhibitortype 2 diabetes

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinGalectin 3BiomarkersSodium-Glucose Transporter 2 InhibitorsLGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.

ORCID-Profile: Paul M Haller

Förderung

  • Deutsche Forschungsgemeinschaft
  • AstraZeneca
  • Abbott Laboratories

Zitieren

APA

Haller, P. M., Wiviott, S. D., Berg, D. D., Jarolim, P., Goodrich, E. L., Bhatt, D. L., Gause-Nilsson, I., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Raz, I., Sabatine, M. S., & Morrow, D. A. (2025). Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58. ESC Heart Failure, 12(6), 3981-3986. https://doi.org/10.1002/ehf2.15415

Vancouver

Haller PM, Wiviott SD, Berg DD, Jarolim P, Goodrich EL, Bhatt DL, et al. Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58. ESC Heart Failure. 2025;12(6):3981-3986. doi:10.1002/ehf2.15415

BibTeX
@article{Haller2025,
  author = {Haller, Paul M and Wiviott, Stephen D and Berg, David D and Jarolim, Petr and Goodrich, Erica L and Bhatt, Deepak L and Gause-Nilsson, Ingrid and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P H and Raz, Itamar and Sabatine, Marc S and Morrow, David A},
  title = {Galectin-3 and Kidney Function in Type 2 Diabetes Treated with Dapagliflozin: Analysis from DECLARE-TIMI 58},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {6},
  pages = {3981--3986},
  doi = {10.1002/ehf2.15415}
}
Kostenlos starten →